技术辅助网络应用助力消费者自选非处方他汀
TACTiC 前瞻性实际使用研究纳入 1196 名无医学背景消费者,通过技术辅助自选网络应用判断是否适合中等强度他汀。初始自选与临床医生评估一致率 90.7%,最终使用一致率 98.1%,LDL-C 平均降低 35.5%,严重不良事件 2.3% 且均与药物无关。
要点
- 网络应用使 >90% 消费者正确自选他汀,最终一致率 98.1%。
- LDL-C 平均降低 35.5%(95%CI -36.6% 至 -34.3%)。
- 严重不良事件 2.3%,均与研究药物无关。
核心结论
- 技术辅助网络应用可让 >90% 消费者正确自选他汀使用,并实现临床重要的 LDL-C 降低。
研究设计与样本
- 前瞻性实际使用 6 个月研究,评估无医学背景者用网络应用按现行指南自选中等强度他汀的资格。
主要发现
- 初始网络应用自选与临床医生评估一致率 90.7%(95%CI 88.9%-92.3%)。
- 治疗期间最终使用结局一致率 98.1%(95%CI 97.1%-98.8%)。
- LDL-C 平均变化百分比 -35.5%(95%CI -36.6% 至 -34.3%)。
- 严重不良事件 27 例(2.3%),均与研究药物无关。
关键数值与推荐
- 参与者中位年龄 63 岁(Q1-Q3 57-68),女性 39.6%,白人 79.3%,黑人 11.7%,识字有限 4.1%。
- 平均 LDL-C 139.6 ± 28.3 mg/dL,中位 10 年 ASCVD 风险 10.1%(Q1-Q3 7.3%-14.0%)。
- 网络应用根据人口学、胆固醇值、血压和合并用药输出「不要使用」「询问医生」「可以使用」三种结果。
临床怎么用
- 可考虑用技术辅助自选工具帮助消费者获取非处方他汀,但需结合临床医生评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although statins reduce adverse cardiovascular outcomes, less than one-half of eligible patients receive treatment. A nonprescription statin has the potential to improve access to statins. OBJECTIVES: This study sought to assess concordance between clinician and consumer assessment of eligibility for nonprescription statin treatment using a technology assisted self-selection Web application (Web App) and evaluate effect on low-density lipoprotein cholesterol (LDL-C) levels. METHODS: This study was a prospective actual use 6-month study to evaluate use of a Web App to qualify participants without a medical background for a moderate-intensity statin based on current guidelines. Participants entered demographic information, cholesterol values, blood pressure, and concomitant medications into the Web App, resulting in 3 possible outcomes: "do not use," "ask a doctor," and "OK to use." RESULTS: The study included 1,196 participants, with a median age of 63 years (Q1-Q3: 57-68 years); 39.6% were women, 79.3% were White, 11.7% were Black, and 4.1% had limited literacy. Mean LDL-C was 139.6 ± 28.3 mg/dL and the median calculated 10-year risk of atherosclerotic cardiovascular disease was 10.1% (Q1-Q3: 7.3%-14.0%). Initial Web App self-selection resulted in an outcome concordant with clinician assessment in 90.7% (95% CI: 88.9%-92.3%) of participants, and 98.1% (95% CI: 97.1%-98.8%) had a concordant final use outcome during treatment. Mean percent change in LDL-C was -35.5% (95% CI: -36.6% to -34.3%). Serious adverse events occurred in 27 (2.3%) participants, none related to the study drug. CONCLUSIONS: In this actual use study, a technology-assisted Web App allowed >90% of consumers to correctly self-select for statin use and achieve clinically important LDL-C reductions. (Technology-Assisted Cholesterol Trial in Consumers [TACTiC]; NCT04964544).
引用
- Nissen SE, Hutchinson HG, Wolski K, et al. A Technology-Assisted Web Application for Consumer Access to a Nonprescription Statin Medication. J Am Coll Cardiol. 2024. PMID: 38599257. doi:10.1016/j.jacc.2024.03.388
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。